People with higher blood levels of certain manufactured compounds that persist in the environment are more likely to be ...

A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...

Kesimpta is a medication used to treat relapsing forms of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Kesimpta comes as a solution inside single-dose prefilled injection pens or ...

B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity and ...

BOSTON--(BUSINESS WIRE)-- EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of over 30 abstracts from its multiple ...

Household products that promise convenience and protection may be carrying a serious health cost. According to a new study ...

The results showed that people with the highest levels of certain chemicals—especially PFOS, a type of PFAS, and two types of ...

New Swedish research finds that people with highest microplastics and PFAS levels face double the risk of multiple sclerosis ...

In a significant advance for multiple sclerosis (MS) research, a new study has uncovered a potential link between certain initial symptoms and long-term disability outcomes. The research, published in ...

Ocrevus (ocrelizumab) is a long-term treatment for certain forms of multiple sclerosis and clinically isolated syndrome. Some people can safely take the drug for more than 10 years. Certain factors ...

– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over ...